Pattern of Use of Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients in UK General Practices

Trial Profile

Pattern of Use of Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients in UK General Practices

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Apixaban; Dabigatran etexilate
  • Indications Stroke
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 20 Nov 2017 Planned patient number changed from 3000 to 31336.
    • 20 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 22 Sep 2017 Planned End Date changed from 30 Aug 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top